Another longitudinal study examining five melanoma patients with acquired resistance to ICB reported a patient with two frameshift mutations in B2M and a second patient harboring a single B2M loss with two frameshift mutations during progression, which resulted in a significant reduction in tumor expression of B2M and a lack of HLA class I protein expression on the outer membrane (65). This evidence concerns the gene B2M and neoplasm.